Syros Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Syros Pharmaceuticals

10/05/2023 14:32

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of 85 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of $1.09 per share.
    * Revenue rose 8.9% to $5.95 million from a year ago;
analysts
expected $3.26 million. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 85 cents​.
    * The mean earnings estimate of analysts had risen by
about 15% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Syros Pharmaceuticals Inc shares had risen by 16.5% this
quarter and lost 13.4% so far this year.
    * The company reported a quarterly loss of $23.79 million.
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.09          -0.85          Beat
 Dec. 31 2022      -1.35          -0.17          Beat
 Sep. 30 2022      -4.01          -3.21          Beat
 Jun. 30 2022      -4.08          -5.40          Missed